Exousia Bio, Inc. (LMMY) intrinsic value & 10-year financials
Exousia Bio, Inc. (LMMY) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 4 fiscal years revenue shrank 67.4% a year to $3.8K, with an average return on invested capital of 85.5%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $0.02
- Market cap
- $136.1K
- Revenue (FY2025)
- $3.8K
- Revenue growth (4-yr CAGR)
- -67.4%
- ROIC (10-yr avg)
- 85.5%
- Free cash flow (FY2025)
- —
LMMY 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.8K | $51.4K | $0.00 | — | — | -187.2% |
| FY2024 | $11.5K | -$25.8K | $0.00 | — | — | 61.5% |
| FY2023 | $0 | -$56.4K | $0.00 | — | — | 382.2% |
| FY2022 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Exousia Bio, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Exousia Bio, Inc. has earned high returns on invested capital, averaging 21.1% ROIC over the available history. High ROIC is consistent with a durable franchise, but it is not by itself proof of an economic moat.
Exousia Bio, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Exousia Bio, Inc. is modeled at -67.4% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.00 per share.